| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/12/2001 | CA2383306A1 Novel pharmaceutical compositions |
| 04/12/2001 | CA2379971A1 Hybrid matrices and hybrid matrix mixtures |
| 04/12/2001 | CA2351075A1 Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications |
| 04/11/2001 | EP1090645A2 Oral delivery of chemically modified proteins |
| 04/11/2001 | EP1090637A2 Compositions and methods for treating or preventing inflammatory diseases |
| 04/11/2001 | EP1090636A1 High lipid diet |
| 04/11/2001 | EP1090085A1 Environmentally preferred fluids and fluid blends |
| 04/11/2001 | EP1090041A1 Novel derivatives of cyclodextrins |
| 04/11/2001 | EP1090038A2 Bispecific antibodies for retargeting anticancer cytotoxic lymphocytes and hybriomas and monoclonal antibodies therefore |
| 04/11/2001 | EP1090037A1 Divalent antibody fragments |
| 04/11/2001 | EP1090036A2 Site specific protein modification by mutagenesis |
| 04/11/2001 | EP1090032A2 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| 04/11/2001 | EP1089766A2 Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| 04/11/2001 | EP1089762A1 Konjugat |
| 04/11/2001 | EP1089749A1 Novel therapeutic agents for membrane transporters |
| 04/11/2001 | EP1089747A1 Compounds obtained from salvia species having antiviral activity |
| 04/11/2001 | EP1089745A1 Oregano for the treatment of internal parasites and protozoa |
| 04/11/2001 | EP1089740A1 TREATMENT OF $i(C. DIFFICILE) TOXIN B ASSOCIATED CONDITIONS |
| 04/11/2001 | EP1089734A2 Use of tempo and tempo derivatives for inducing cell death |
| 04/11/2001 | EP1089722A1 Matrix-type transdermal patch for steroid hormones |
| 04/11/2001 | EP1089719A2 Transdermal therapeutic system containing hormones and crystallization inhibitors |
| 04/11/2001 | EP1089718A1 Sticking plaster for controlled release of natural interferon |
| 04/11/2001 | EP1089715A1 Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| 04/11/2001 | EP1089714A2 Processes to generate submicron particles of water-insoluble compounds |
| 04/11/2001 | EP1089713A1 Temperature-sensitive liposomal formulation |
| 04/11/2001 | EP1089711A1 Calcium phosphate coated vesicles |
| 04/11/2001 | EP1089710A1 Injectable pharmaceutical formulations of partricin derivatives |
| 04/11/2001 | EP1089709A1 Icecream-type pharmaceutical formulation and process for preparing the same |
| 04/11/2001 | EP0918498A4 Improved tissue injectable composition and method of use |
| 04/11/2001 | CN1291228A Enzyme catalyzed therapeutic agents |
| 04/11/2001 | CN1291101A Regulation of estrus and ovulation in gilts |
| 04/11/2001 | CN1291098A Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors |
| 04/11/2001 | CN1291097A Morphine sulphate microgranules, method for making same and pharmaceutical preparations |
| 04/11/2001 | CN1291093A Pig appeasing pheromones to decrease stress, anxiety and aggressiveness |
| 04/11/2001 | CN1291091A Orally administrable immediate and prolonged-release Galenic form comprising absorption-promoting agent and use of this absorption-promoting agent |
| 04/11/2001 | CN1290523A Disposable pharmacotherapeutic nasal suppository |
| 04/11/2001 | CN1064252C Hypoglycemic high calcium granule |
| 04/10/2001 | US6214974 Internalizable cell binding component having biotin binding element conjugated to biotinylated nucleic acids or cytotoxic moieties such as gelonin, ricin, saporin, abrin, diptheria toxin and the like; gene therapy; drug delivery of toxins |
| 04/10/2001 | US6214966 Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| 04/10/2001 | US6214957 Solubilizers, emulsifiers and dispersants |
| 04/10/2001 | US6214874 Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N |
| 04/10/2001 | US6214866 Composition comprising mupirocin and chlorhexidine |
| 04/10/2001 | US6214864 Formulation of dihydroartemisinin for the control of wide spectrum of malaria |
| 04/10/2001 | US6214812 Vitamin b6 bisphosphonate conjugate |
| 04/10/2001 | US6214803 Pharmacological composition for treating cancer cells |
| 04/10/2001 | US6214621 Ionic conjugate which is stable in biological medium; non-liquid cationic hydrophilic nucleus which is crosslinked matrix of poly- or oligosaccharides and a polyanionic oligonucleotide; delivering oligonucleotides to cell |
| 04/10/2001 | US6214614 Cell cycle regulated repressor and DNA element |
| 04/10/2001 | US6214594 Size enhanced fibrinolytic enzymes: limitations of plasma inactivation |
| 04/10/2001 | US6214551 Oligonucleoside linkages containing adjacent nitrogen atoms |
| 04/10/2001 | US6214388 Immunoliposomes that optimize internalization into target cells |
| 04/10/2001 | US6214387 Biodegradable polymer matrices for sustained delivery of local anesthetic agents |
| 04/10/2001 | US6214360 Pharmaceutical composition |
| 04/10/2001 | US6214345 Lysosomal enzyme-cleavable antitumor drug conjugates |
| 04/10/2001 | US6214330 Polymeric-based double prodrugs having reversible linkages involving amino or hydroxyl moieties of chemical compounds and biologically active materials such as enzymes and proteins |
| 04/10/2001 | US6214327 Antibacterial composition |
| 04/10/2001 | US6214318 Comprising mineral oils, vegetable oils, silicone oils or synthetic oils; thickening agents such as waxes to thicken oils to non-flowable state; optionally adjuvants, drugs and emulsifiers and a liquefied propellant; cooling effect |
| 04/10/2001 | US6214315 Radioactive embolizing compositions |
| 04/10/2001 | CA2222299C Novel taxoids |
| 04/10/2001 | CA2210749C Anti-inflammatory eye drop |
| 04/10/2001 | CA2135925C Use of glycerin in moderating transdermal drug delivery |
| 04/10/2001 | CA2074089C Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor |
| 04/10/2001 | CA2064889C Polymeric materials |
| 04/10/2001 | CA2046861C K2p pro stabilisation |
| 04/10/2001 | CA2021942C Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent |
| 04/10/2001 | CA2019410C Liquid polymer composition, and method of use |
| 04/10/2001 | CA1341212C Osteoinductive factors |
| 04/05/2001 | WO2001023362A2 Rate-controlled particles |
| 04/05/2001 | WO2001023005A1 Antibody dye conjugates for binding to target structures of angiogenesis in order to intraoperatively depict tumor peripheries |
| 04/05/2001 | WO2001023001A2 Rapid peg-modification |
| 04/05/2001 | WO2001022999A1 Dermal or transdermal application system containing an iota carragheenate |
| 04/05/2001 | WO2001022998A1 Stable calcitriol solution for packaging in vials |
| 04/05/2001 | WO2001022995A1 A method for preparing conjugates between an antigen and mucosal binding component |
| 04/05/2001 | WO2001022992A2 Influenza vaccine |
| 04/05/2001 | WO2001022989A2 Method to enhance healing of sternum after sternotomy |
| 04/05/2001 | WO2001022986A1 Anti cancer agent and method of treatment of cancer |
| 04/05/2001 | WO2001022969A2 Vasopressin agonist formulation and process |
| 04/05/2001 | WO2001022967A1 Compositions having improved stability |
| 04/05/2001 | WO2001022947A2 Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same |
| 04/05/2001 | WO2001022945A1 Vasopressin antagonist formulation and process |
| 04/05/2001 | WO2001022942A1 Pharmaceutical carrier formulation |
| 04/05/2001 | WO2001022941A1 Melt granulated composition and modified release dosage form prepared from said composition |
| 04/05/2001 | WO2001022940A1 Sustained release matrix systems for highly soluble drugs |
| 04/05/2001 | WO2001022938A1 Antiviral compositions |
| 04/05/2001 | WO2001022937A1 Compositions of tocol-soluble therapeutics |
| 04/05/2001 | WO2001022936A1 Topical suspension formulations containing ciprofloxacin and dexamethasone |
| 04/05/2001 | WO2001022923A2 Scar treatment composition |
| 04/05/2001 | WO2001022922A2 Engineering antibodies that bind irreversibly |
| 04/05/2001 | WO2001022907A1 Drug delivery of phase changing formulation |
| 04/05/2001 | WO2001022791A2 Controlled release compositions comprising nimesulide |
| 04/05/2001 | WO2000072867A3 Substantially oil-free cyclosporin compositions |
| 04/05/2001 | WO2000072820A3 Injectable anesthetic formulation |
| 04/05/2001 | WO2000069914A3 Humanized antibodies specific for egp-2 |
| 04/05/2001 | WO2000069440A3 Nicotine delivery systems |
| 04/05/2001 | WO2000066126A3 Liposome compositions for improved drug retention |
| 04/05/2001 | WO2000056284A3 Potentiation medium |
| 04/05/2001 | WO2000050090A3 Dry acid-chitosan complexes |
| 04/05/2001 | WO2000040228A3 Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions |
| 04/05/2001 | WO2000015036A9 Topical dermal antimicrobial compositions |
| 04/05/2001 | US20010000143 Using dimethyl ether and elevated temperature/pressure to dissolve the solid; releasing the pressure to precipitate the fine powder and expand the ether into a gas; drugs; vitamins; carotenoid, especially beta-carotene; foods; cosmetics |
| 04/05/2001 | DE19945578A1 Kosmetische und/oder pharmazeutische Zubereitungen Cosmetic and / or pharmaceutical preparations |